Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.
Claims27
A genetically modified NK cell transfected with one or more recombinant nucleic acids encoding and expressing
- (i) a membrane bound recombinant chimeric antigen receptor (CAR) that comprises in a single polypeptide chain an extracellular binding domain having SEQ ID NO:41, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain having the polypeptide sequence of SEQ ID NO:1, wherein the extracellular binding domain specifically binds to EGFR;
- (ii) a recombinant CD16;
- (iii) an autocrine growth stimulating cytokine.
A genetically modified NK cell, comprising:
- a recombinant nucleic acid encoding
- (i) a membrane bound recombinant chimeric antigen receptor (CAR) that comprises in a single polypeptide chain an extracellular binding domain having SEQ ID NO:41, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain having the polypeptide sequence of SEQ ID NO:1, wherein the extracellular binding domain specifically binds to EGFR;
- (ii) a recombinant CD16;
- (iii) an autocrine growth stimulating cytokine.
Dependencies are inferred from the claim text.